Remodeling the blood–brain barrier microenvironment by natural products for brain tumor therapy

Acta Pharmaceutica Sinica B

Volumn 7, Issue 5, 2017, Pages 541-553

  Zhao, Xiao ^a   Chen, Rujing ^a   Liu, Mei ^a   Feng, Jianfang ^a   Chen, Jun ^b   Hu, Kaili ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Blood brain barrier; Brain tumors; Extracellular matrix; Glioma; Microenvironment; Natural products

Indexed keywords

AEROPLYSININ 1; BETULIC ACID; BRADYKININ; BRAIN DERIVED NEUROTROPHIC FACTOR; CARYOPHYLLENE; CURCUMIN; EPIDERMAL GROWTH FACTOR; FATTY ACID; FIBRONECTIN; GELATINASE A; GELATINASE B; KAINIC ACID; LACTIC ACID; LEUKOTRIENE; MULTIDRUG RESISTANCE PROTEIN; NATURAL PRODUCT; OSTHOLE; PHOSPHATIDYLINOSITOL 3 KINASE; PROCYANIDIN; PROTEIN KINASE; PROTEIN KINASE B; RESVERATROL; SALICIN; SHIKONIN; TEMOZOLOMIDE; TENASCIN; TRICHOSANTHIN; TROPOMYOSIN RELATED KINASE B; UNCLASSIFIED DRUG; UNINDEXED DRUG; WITHANIA SOMNIFERA EXTRACT;

ANTIPROLIFERATIVE ACTIVITY; ASTROCYTE; ASTROCYTOMA; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CELL MIGRATION; CELL PROLIFERATION; DRUG PENETRATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GLIOMA; GLIOMA STEM CELL; HUMAN; INTRACRANIAL PRESSURE; MACROPHAGE; MICROGLIA; MIGRATION INHIBITION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PINOCYTOSIS; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WNT SIGNALING;

EID: 85028604701     PISSN: 22113835     EISSN: 22113843     Source Type: Journal    
DOI: 10.1016/j.apsb.2017.07.002     Document Type: Review

References (168)

1. Gittleman, H., Ostrom, Q.T., Farah, P.D., Ondracek, A., Chen, Y., Wolinsky, Y., et al. Descriptive epidemiology of pituitary tumors in the United States, 2004–2009. J Neurosurg 121 (2014), 527–535.
2. Williams, M.J., Singleton, W.G., Lowis, S.P., Malik, K., Kurian, K.M., Therapeutic targeting of histone modifications in adult and pediatric high-grade glioma. Front Oncol, 7, 2017, 45.
3. Fangusaro, J., Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology. Front Oncol, 2, 2012, 105.
4. Chow, B.W., Gu, C., The molecular constituents of the blood–brain barrier. Trends Neurosci 38 (2015), 598–608.
5. Obermeier, B., Daneman, R., Ransohoff, R.M., Development, maintenance and disruption of the blood–brain barrier. Nat Med 19 (2013), 1584–1596.
6. Schinkel, A.H., P-Glycoprotein, a gatekeeper in the blood–brain barrier. Adv Drug Deliv Rev 36 (1999), 179–194.
7. Tamai, I., Tsuji, A., Transporter-mediated permeation of drugs across the blood–brain barrier. J Pharm Sci 89 (2000), 1371–1388.
8. Fidler, I.J., The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 21 (2011), 107–112.
9. Alvarez, J.I., Cayrol, R., Prat, A., Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta Mol Basis Dis 1812 (2011), 252–264.
10. Lécuyer, M.A., Kebir, H., Prat, A., Glial influences on BBB functions and molecular players in immune cell trafficking. Biochim Biophys Acta Mol Basis Dis 1862 (2016), 472–482.
11. ElAli, A., Thériault, P., Rivest, S., The role of pericytes in neurovascular unit remodeling in brain disorders. Int J Mol Sci 15 (2014), 6453–6474.
12. Stankovic, D.N., Teodorczyk, M., Ploen, R., Zipp, F., Schmidt, M.H., Microglia–blood vessel interactions: a double-edged sword in brain pathologies. Acta Neuropathol 131 (2016), 347–363.
13. Beliën, A.T., Paganetti, P.A., Schwab, M.E., Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J Cell Biol 144 (1999), 373–384.
14. Sameshima, T., Nabeshima, K., Toole, B.P., Yokogami, K., Okada, Y., Goya, T., et al. Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. Cancer Lett 157 (2000), 177–184.
15. Abbott, N.J., Patabendige, A.A., Dolman, D.E., Yusof, S.R., Begley, D.J., Structure and function of the blood–brain barrier. Neurobiol Dis 37 (2010), 13–25.
16. Arismendi-Morillo, G., Hoa, N.T., Ge, L., Jadus, M.R., Mitochondrial network in glioma's invadopodia displays an activated state both in situ and in vitro: potential functional implications. Ultrastruct Pathol 36 (2012), 409–414.
17. Takeuchi, H., Kubota, T., Sato, K., Arishima, H., Ultrastructure of capillary endothelium in pilocytic astrocytomas. Brain Tumor Pathol 21 (2004), 23–26.
18. Klumpp, L., Sezgin, E.C., Eckert, F., Huber, S.M., Ion channels in brain metastasis. Int J Mol Sci, 17, 2016, 1513.
19. Chow, D.S., Horenstein, C.I., Canoll, P., Lignelli, A., Hillman, E.M., Filippi, C.G., et al. Glioblastoma induces vascular dysregulation in nonenhancing peritumoral regions in humans. Am J Roentgenol 206 (2016), 1073–1081.
20. Jacobs, V.L., Landry, R.P., Liu, Y., Romero-Sandoval, E.A., De Leo, J.A., Propentofylline decreases tumor growth in a rodent model of glioblastoma multiforme by a direct mechanism on microglia. Neuro Oncol 14 (2012), 119–131.
21. Yu, F., Li, G., Gao, J., Sun, Y., Liu, P., Gao, H., et al. SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and temozolomide resistance. Cell Prolif 49 (2016), 195–206.
22. El Hindy, N., Keyvani, K., Pagenstecher, A., Hindy, P., Sandalcioglu, I.E., Sure, U., et al. Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme. Neuro Oncol 15 (2013), 1366–1378.
23. Pham, K., Luo, D., Liu, C., Harrison, J.K., CCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5. J Neuroimmunol 246 (2012), 10–17.
24. Spano, D., Zollo, M., Tumor microenvironment: a main actor in the metastasis process. Clin Exp Metastas- 29 (2012), 381–395.
25. De, I., Steffen, M.D., Clark, P.A., Patros, C.J., Sokn, E., Bishop, S.M., et al. CSF1 overexpression promotes high-grade glioma formation without impacting the polarization status of glioma-associated microglia and macrophages. Cancer Res 76 (2016), 2552–2560.
26. Glass, R., Synowitz, M., CNS macrophages and peripheral myeloid cells in brain tumours. Acta Neuropathol 128 (2014), 347–362.
27. Schlageter, K.E., Molnar, P., Lapin, G.D., Groothuis, D.R., Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 58 (1999), 312–328.
28. Charles, N.A., Holland, E.C., Gilbertson, R., Glass, R., Kettenmann, H., The brain tumor microenvironment. Glia 60 (2012), 502–514.
29. Rolón-Reyes, K., Kucheryavykh, Y.V., Cubano, L.A., Inyushin, M., Skatchkov, S.N., Eaton, M.J., et al. Microglia activate migration of glioma cells through a Pyk2 intracellular pathway. PLoS One, 10, 2015, e0131059.
30. Kees, T., Lohr, J., Noack, J., Mora, R., Gdynia, G., Tödt, G., et al. Microglia isolated from patients with glioma gain antitumor activities on poly (I:c) stimulation. Neuro Oncol 14 (2012), 64–78.
31. Yamada, T., Yoshiyama, Y., Sato, H., Seiki, M., Shinagawa, A., Takahashi, M., White matter microglia produce membrane-type matrix metalloprotease, an activator of gelatinase A, in human brain tissues. Acta Neuropathol 90 (1995), 421–424.
32. Bayerl, S.H., Niesner, R., Cseresnyes, Z., Radbruch, H., Pohlan, J., Brandenburg, S., et al. Time lapse in vivo microscopy reveals distinct dynamics of microglia-tumor environment interactions—a new role for the tumor perivascular space as highway for trafficking microglia. Glia 64 (2016), 1210–1226.
33. Sin, W.C., Aftab, Q., Bechberger, J.F., Leung, J.H., Chen, H., Naus, C.C., Astrocytes promote glioma invasion via the gap junction protein connexin43. Oncogene 35 (2016), 1504–1516.
34. Lu, P., Wang, Y., Liu, X., Wang, H., Zhang, X., Wang, K., et al. Malignant gliomas induce and exploit astrocytic mesenchymal-like transition by activating canonical Wnt/β-catenin signaling. Med Oncol, 33, 2016, 66.
35. Barbero, S., Bajetto, A., Bonavia, R., Porcile, C., Piccioli, P., Pirani, P., et al. Expression of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1 in human brain tumors and their involvement in glial proliferation in vitro. Ann New Y Acad Sci 973 (2002), 60–69.
36. Hoelzinger, D.B., Demuth, T., Berens, M.E., Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 99 (2007), 1583–1593.
37. Emdad, L., Sarkar, D., Su, Z.Z., Lee, D.C., Kang, D.C., Bruce, J.N., et al. Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol Ther 114 (2007), 155–170.
38. Rempel, S.A., Dudas, S., Ge, S., Gutiérrez, J.A., Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 6 (2000), 102–111.
39. O'Brien, E.R., Howarth, C., Sibson, N.R., The role of astrocytes in CNS tumors: pre-clinical models and novel imaging approaches. Front Cell Neurosci, 7, 2013, 40.
40. Nagashima, G., Suzuki, R., Asai, J., Fujimoto, T., Immunohistochemical analysis of reactive astrocytes around glioblastoma: an immunohistochemical study of postmortem glioblastoma cases. Clin Neurol Neurosurg 104 (2002), 125–131.
41. Gimsa, U., Mitchison, N.A., Brunner-Weinzierl, M.C., Immune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-cell-mediated neuroinflammation. Mediat Inflamm, 2013, 2013, 320519.
42. Rousselet, E., Traver, S., Monnet, Y., Perrin, A., Mandjee, N., Hild, A., et al. Tumor necrosis factor-like weak inducer of apoptosis induces astrocyte proliferation through the activation of transforming-growth factor-α/epidermal growth factor receptor signaling pathway. Mol Pharmacol 82 (2012), 948–957.
43. Guizzetti, M., Kavanagh, T.J., Costa, L.G., Measurements of astrocyte proliferation. Costa, L.G., Giordano, G., Guizzetti, M., (eds.) In vitro neurotoxicology, 2011, Humana Press, New York.
44. Buckingham, S.C., Robel, S., Glutamate and tumor-associated epilepsy: glial cell dysfunction in the peritumoral environment. Neurochem Int 63 (2013), 696–701.
45. Couldwell, W.T., Yong, V.W., Dore-Duffy, P., Freedman, M.S., Antel, J.P., Production of soluble autocrine inhibitory factors by human glioma cell lines. J Neurol Sci 110 (1992), 178–185.
46. Lal, P.G., Ghirnikar, R.S., Eng, L.F., Astrocyte-astrocytoma cell line interactions in culture. J Neurosci Res 44 (1996), 216–222.
47. Le, D.M., Besson, A., Fogg, D.K., Choi, K.S., Waisman, D.M., Goodyer, C.G., et al. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. J Neurosci 23 (2003), 4034–4043.
48. Lapa, C., Linsenmann, T., Lückerath, K., Samnick, S., Herrmann, K., Stoffer, C., et al. Tumor-associated macrophages in glioblastoma multiforme—a suitable target for somatostatin receptor-based imaging and therapy?. PLoS One, 10, 2015, e0122269.
49. Pang, L., Qin, J., Han, L., Zhao, W., Liang, J., Xie, Z., et al. Exploiting macrophages as targeted carrier to guide nanoparticles into glioma. Oncotarget 7 (2016), 37081–37091.
50. Gabrusiewicz, K., Hossain, M.B., Cortes-Santiago, N., Fan, X., Kaminska, B., Marini, F.C., et al. Macrophage ablation reduces M2-Like populations and jeopardizes tumor growth in a MAFIA-based glioma model. Neoplasia 17 (2015), 374–384.
51. Infanger, D.W., Cho, Y., Lopez, B.S., Mohanan, S., Liu, S.C., Gursel, D., et al. Glioblastoma stem cells are regulated by interleukin-8 signaling in a tumoral perivascular niche. Cancer Res 73 (2013), 7079–7089.
52. Rape, A., Ananthanarayanan, B., Kumar, S., Engineering strategies to mimic the glioblastoma microenvironment. Adv Drug Deliv Rev 79–80 (2014), 172–183.
53. Nico, B., Ribatti, D., Morphofunctional aspects of the blood–brain barrier. Curr Drug Metab 13 (2012), 50–60.
54. Van Tellingen, O., Yetkin-Arik, B., De Gooijer, M.C., Wesseling, P., Wurdinger, T., de Vries, H.E., Overcoming the blood–brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat 19 (2015), 1–12.
55. + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7 (2005), 870–879.
56. Vannini, E., Olimpico, F., Middei, S., Ammassari-Teule, M., de Graaf, E.L., McDonnell, L., et al. Electrophysiology of glioma: a Rho GTPase-activating protein reduces tumor growth and spares neuron structure and function. Neuro Oncol 18 (2016), 1634–1643.
57. Dilmanian, F.A., Button, T.M., Le Duc, G., Zhong, N., Peña, L.A., Smith, J.A., et al. Response of rat intracranial 9L gliosarcoma to microbeam radiation therapy. Neuro Oncol 4 (2002), 26–38.
58. Giese, A., Loo, M.A., Rief, M.D., Tran, N., Berens, M.E., Substrates for astrocytoma invasion. Neurosurgery 37 (1995), 294–302.
59. Koochekpour, S., Pilkington, G.J., Merzak, A., Hyaluronic acid/CD44H interaction induces cell detachment and stimulates migration and invasion of human glioma cells in vitro. Int J Cancer 63 (1995), 450–454.
60. Zhou, Y., Larsen, P.H., Hao, C., Yong, V.W., CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 277 (2002), 49481–49487.
61. Schwarzbauer, J.E., Alternative splicing of fibronectin: three variants, three functions. Bioessays 13 (1991), 527–533.
62. Ding, D., Kanaly, C.W., Bigner, D.D., Cummings, T.J., Herndon, J.E., Pastan, I., et al. Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. J Neuro-Oncol 98 (2010), 1–7.
63. Bourdon, M.A., Wikstrand, C.J., Furthmayr, H., Matthews, T.J., Bigner, D.D., Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 43 (1983), 2796–2805.
64. Serwer, L.P., James, C.D., Challenges in drug delivery to tumors of the central nervous system: an overview of pharmacological and surgical considerations. Adv Drug Deliv Rev 64 (2012), 590–597.
65. White, E.S., Muro, A.F., Fibronectin splice variants: understanding their multiple roles in health and disease using engineered mouse models. IUBMB Life 63 (2011), 538–546.
66. a (EIIIA): complementarity to plasma fibronectin functions. Exp Cell Res 217 (1995), 517–527.
67. Serini, G., Bochaton-Piallat, M.L., Ropraz, P., Geinoz, A., Borsi, L., Zardi, L., et al. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-β1. J Cell Biol, 142, 1998, 873–881.
68. Manabe, R., Oh-e, N., Sekiguchi, K., Alternatively spliced EDA segment regulates fibronectin-dependent cell cycle progression and mitogenic signal transduction. J Biol Chem 274 (1999), 5919–5924.
69. Fukuda, T., Yoshida, N., Kataoka, Y., Manabe, R., Mizuno-Horikawa, Y., Sato, M., et al. Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. Cancer Res 62 (2002), 5603–5610.
70. Khan, Z.A., Chan, B.M., Uniyal, S., Barbin, Y.P., Farhangkhoee, H., Chen, S., et al. EDB fibronectin and angiogenesis—a novel mechanistic pathway. Angiogenesis 8 (2005), 183–196.
71. Kuusela, P., Ruoslahti, E., Vaheri, A., Polypeptides of a glycoprotein antigen (SF) present in serum and surface of normal but not of transformed chicken fibroblasts. Biochim Biophys Acta Prot Struct 379 (1975), 295–303.
72. Vander, H.M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324 (2009), 1029–1033.
73. Kim, J., DeBerardinis, R.J., Blocking fatty acid synthesis reduces lung tumor growth in mice. Nat Med 22 (2016), 1077–1078.
74. Apostolova, I., Irintchev, A., Schachner, M., Tenascin-R restricts posttraumatic remodeling of motoneuron innervation and functional recovery after spinal cord injury in adult mice. J Neurosci 26 (2006), 7849–7859.
75. Xia, S., Lal, B., Tung, B., Wang, S., Goodwin, C.R., Laterra, J., Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation. Neuro Oncol 18 (2016), 507–517.
76. Rolle, K., Nowak, S., Wyszko, E., Nowak, M., Zukiel, R., Piestrzeniewicz, R., et al. Promising human brain tumors therapy with interference RNA intervention (iRNAi). Cancer Biol Ther 9 (2010), 397–407.
77. 4. Reulen, H.J., Baethmann, A., Fenstermacher, J., Marmarou, A., Spatz, M., (eds.) Brain edema VIII. Acta neurochirurgica, 1990, Springer, Vienna, 140–141.
78. Nakano, S., Matsukado, K., Black, K.L., Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res 56 (1996), 4027–4031.
79. Machein, M.R., Kullmer, J., Fiebich, B.L., Plate, K.H., Warnke, P.C., Vascular endothelial growth factor expression, vascular volume, and capillary permeability in human brain tumors. Neurosurgery 44 (1999), 732–741.
80. Demeule, M., Régina, A., Jodoin, J., Laplante, A., Dagenais, C., Berthelet, F., et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood–brain barrier. Vasc Pharmacol 38 (2002), 339–348.
81. Kacem, K., Lacombe, P., Seylaz, J., Bonvento, G., Structural organization of the perivascular astrocyte endfeet and their relationship with the endothelial glucose transporter: a confocal microscopy study. Glia 23 (1998), 1–10.
82. Abbott, N.J., Rönnbäck, L., Hansson, E., Astrocyte–endothelial interactions at the blood–brain barrier. Nat Rev Neurosci 7 (2006), 41–53.
83. Montagne, A., Barnes, S.R., Sweeney, M.D., Halliday, M.R., Sagare, A.P., Zhao, Z., et al. Blood–brain barrier breakdown in the aging human hippocampus. Neuron 85 (2015), 296–302.
84. Sanchez-Covarrubias, L., Slosky, L.M., Thompson, B.J., Davis, T.P., Ronaldson, P.T., Transporters at CNS barrier sites: obstacles or opportunities for drug delivery. Curr Pharm Des 20 (2014), 1422–1449.
85. Ronaldson, P.T., Davis, T.P., Blood–brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke. Curr Pharm Des 18 (2012), 3624–3644.
86. Huber, J.D., Campos, C.R., Mark, K.S., Davis, T.P., Alterations in blood–brain barrier ICAM-1 expression and brain microglial activation after lambda-carrageenan-induced inflammatory pain. Am J Physiol Heart Circ Physiol 290 (2006), H732–H740.
87. Erdő F., Denes, L., De Lange, E., Age-associated physiological and pathological changes at the blood–brain barrier: a review. J Cereb Blood Flow Metab 37 (2017), 4–24.
88. Kucharzewska, P., Christianson, H.C., Welch, J.E., Svensson, K.J., Fredlund, E., Ringnér, M., et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci USA 110 (2013), 7312–7317.
89. Svensson, A., Özen, I., Genové G., Paul, G., Bengzon, J., Endogenous brain pericytes are widely activated and contribute to mouse glioma microvasculature. PLoS One, 10, 2015, e0123553.
90. Tae, N., Lee, S., Kim, O., Park, J., Na, S., Lee, J.H., Syntenin promotes VEGF-induced VEGFR2 endocytosis and angiogenesis by increasing ephrin-B2 function in endothelial cells. Oncotarget 8 (2017), 38886–38901.
91. Xie, H., Cui, Y., Hou, S., Wang, J., Miao, J., Deng, F., et al. Evaluation of connexin 43 redistribution and endocytosis in astrocytes subjected to ischemia/reperfusion or oxygen-glucose deprivation and reoxygenation. Biomed Res Int, 2017, 2017, 5064683.
92. Cui, X., Wan, B., Yang, Y., Ren, X., Guo, L.H., Length effects on the dynamic process of cellular uptake and exocytosis of single-walled carbon nanotubes in murine macrophage cells. Sci Rep, 7, 2017, 1518.
93. Candela, P., Saint-Pol, J., Kuntz, M., Boucau, M.C., Lamartiniere, Y., Gosselet, F., et al. In vitro discrimination of the role of LRP1 at the BBB cellular level: focus on brain capillary endothelial cells and brain pericytes. Brain Res 1594 (2015), 15–26.
94. Hilgemann, D.W., Fine, M., Linder, M.E., Jennings, B.C., Lin, M.J., Massive endocytosis triggered by surface membrane palmitoylation under mitochondrial control in BHK fibroblasts. Elife, 2, 2013, e01293.
95. Wu, X.S., Zhang, Z., Zhao, W.D., Wang, D., Luo, F., Wu, L.G., Calcineurin is universally involved in vesicle endocytosis at neuronal and nonneuronal secretory cells. Cell Rep 7 (2014), 982–988.
96. Kawabe K, Takano K, Moriyama M, Nakamura Y. Microglia endocytose amyloid β through the binding of transglutaminase 2 and milk fat globule EGF factor 8 protein. Neurochem Res 2017. Available form: 10.1007/s11064-017-2284-y.
97. Zhang, F.Y., Hu, Y., Que, Z.Y., Wang, P., Liu, Y.H., Wang, Z.H., et al. Shikonin inhibits the migration and invasion of human glioblastoma cells by targeting phosphorylated β-catenin and phosphorylated PI3K/Akt: a potential mechanism for the anti-glioma efficacy of a traditional Chinese herbal medicine. Int J Mol Sci 16 (2015), 23823–23848.
98. Choi, Y.W., Lee, K.P., Kim, J.M., Kang, S., Park, S.J., Lee, J.M., et al. Petatewalide B, a novel compound from Petasites japonicus with anti-allergic activity. J Ethnopharmacol 178 (2016), 17–24.
99. Matias, D., Balça-Silva, J., Dubois, L.G., Pontes, B., Ferrer, V.P., Rosário, L., et al. Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition. Cell Oncol 40 (2017), 247–261.
100. Wang, L., Li, Z., Zhang, X., Wang, S., Zhu, C., Miao, J., et al. Protective effect of shikonin in experimental ischemic stroke: attenuated TLR4, p-p38MAPK, NF-κB, TNF-α and MMP-9 expression, up-regulated claudin-5 expression, ameliorated BBB permeability. Neurochem Res 39 (2014), 97–106.
101. Lin, K., Gao, Z., Shang, B., Sui, S., Fu, Q., Osthole suppresses the proliferation and accelerates the apoptosis of human glioma cells via the upregulation of microRNA-16 and downregulation of MMP-9. Mol Med Rep 12 (2015), 4592–4597.
102. Duan, J., Yang, Y., Liu, H., Dou, P.C., Tan, S.Y., Osthole ameliorates acute myocardial infarction in rats by decreasing the expression of inflammatory-related cytokines, diminishing MMP-2 expression and activating p-ERK. Int J Mol Med 37 (2016), 207–216.
103. Chen, R., Xue, J., Xie, M., Osthole regulates TGF-β1 and MMP-2/9 expressions via activation of PPARα/γ in cultured mouse cardiac fibroblasts stimulated with angiotensin II. J Pharm Pharm Sci 16 (2013), 732–741.
104. Xu, X.M., Zhang, Y., Qu, D., Feng, X.W., Chen, Y., Zhao, L., Osthole suppresses migration and invasion of A549 human lung cancer cells through inhibition of matrix metalloproteinase-2 and matrix metallopeptidase-9 in vitro. Mol Med Rep 6 (2012), 1018–1022.
105. Kao, S.J., Su, J.L., Chen, C.K., Yu, M.C., Bai, K.J., Chang, J.H., et al. Osthole inhibits the invasive ability of human lung adenocarcinoma cells via suppression of NF-κB-mediated matrix metalloproteinase-9 expression. Toxicol Appl Pharmacol 261 (2012), 105–115.
106. Yang, D., Gu, T., Wang, T., Tang, Q., Ma, C., Effects of osthole on migration and invasion in breast cancer cells. Biosci Biotechnol Biochem 74 (2010), 1430–1434.
107. Jang, M., Cai, L., Udeani, G.O., Slowing, K.V., Thomas, C.F., Beecher, C.W.W., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275 (1997), 218–220.
108. 4 hydrolase. Cancer Res 70 (2010), 9755–9764.
109. Puissant, A., Robert, G., Fenouille, N., Luciano, F., Cassuto, J.P., Raynaud, S., et al. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 70 (2010), 1042–1052.
110. Hao, X.N., Wang, W.J., Chen, J., Zhou, Q., Qu, Y.X., Liu, X.Y., et al. Effects of resveratrol on ARPE-19 cell proliferation and migration via regulating the expression of proliferating cell nuclear antigen, P21, P27 and p38MAPK/MMP-9. Int J Ophthalmol 9 (2016), 1725–1731.
111. Jiao, Y., Li, H., Liu, Y., Guo, A., Xu, X., Qu, X., et al. Resveratrol inhibits the invasion of glioblastoma-initiating cells via down-regulation of the PI3K/Akt/NF-κB signaling pathway. Nutrients 7 (2015), 4383–4402.
112. Wei, H., Wang, S., Zhen, L., Yang, Q., Wu, Z., Lei, X., et al. Resveratrol attenuates the blood–brain barrier dysfunction by regulation of the MMP-9/TIMP-1 balance after cerebral ischemia reperfusion in rats. J Mol Neurosci 55 (2015), 872–879.
113. Gentile, E., Liuzzi, G.M., Marine pharmacology: therapeutic targeting of matrix metalloproteinases in neuroinflammation. Drug Discov Today 22 (2017), 299–313.
114. Rodríguez-Nieto, S., González-Iriarte, M., Carmona, R., Muñoz-Chápuli, R., Medina, M.A., Quesada, A.R., Antiangiogenic activity of aeroplysinin-1, a brominated compound isolated from a marine sponge. FASEB J 16 (2002), 261–263.
115. Martínez-Poveda, B., García-Vilas, J.A., Cárdenas, C., Melgarejo, E., Quesada, A.R., Medina, M.A., The brominated compound aeroplysinin-1 inhibits proliferation and the expression of key pro-inflammatory molecules in human endothelial and monocyte cells. PLoS One, 8, 2013, e55203.
116. Zheng, H.L., Yang, J., Hou, Y., Sun, B., Zhang, Q., Mou, Y., et al. Oligomer procyanidins (F2) isolated from grape seeds inhibits tumor angiogenesis and cell invasion by targeting HIF-1α in vitro. Int J Oncol 46 (2015), 708–720.
117. Liu, Y., Tao, L., Fu, X., Zhao, Y., Xu, X., BDNF protects retinal neurons from hyperglycemia through the TrkB/ERK/MAPK pathway. Mol Med Rep 7 (2013), 1773–1778.
118. Yoshii, A., Constantine-Paton, M., Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol 70 (2010), 304–322.
119. Sun, X., Zhou, H., Luo, X., Li, S., Yu, D., Hua, J., et al. Neuroprotection of brain-derived neurotrophic factor against hypoxic injury in vitro requires activation of extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. Int J Dev Neurosci 26 (2008), 363–370.
120. Almeida, R.D., Manadas, B.J., Melo, C.V., Gomes, J.R., Mendes, C.S., Grãos, M.M., et al. Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ 12 (2005), 1329–1343.
121. Bonni, A., Brunet, A., West, A.E., Datta, S.R., Takasu, M.A., Greenberg, M.E., Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286 (1999), 1358–1362.
122. Satoh, T., Nakatsuka, D., Watanabe, Y., Nagata, I., Kikuchi, H., Namura, S., Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons. Neurosci Lett 288 (2000), 163–166.
123. Jin, K., Mao, X.O., Zhu, Y., Greenberg, D.A., MEK and ERK protect hypoxic cortical neurons via phosphorylation of Bad. J Neurochem 80 (2002), 119–125.
124. Klöcker, N., Kermer, P., Weishaupt, J.H., Labes, M., Ankerhold, R., Bähr, M., Brain-derived neurotrophic factor-mediated neuroprotection of adult rat retinal ganglion cells in vivo does not exclusively depend on phosphatidyl-inositol-3ʹ-kinase/protein kinase B signaling. J Neurosci 20 (2000), 6962–6967.
125. Baird, L., Dinkova-Kostova, A.T., The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol 85 (2011), 241–272.
126. Li, W., Ma, J., Ma, Q., Li, B., Han, L., Liu, J., et al. Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-κB pathway. Curr Med Chem 20 (2013), 4185–4194.
127. Gilmore, T.D., Introduction to NF-κB: players, pathways, perspectives. Oncogene 25 (2006), 6680–6684.
128. Karin, M., Nuclear factor-κB in cancer development and progression. Nature 441 (2006), 431–436.
129. Zhou, T., Yang, Y., Zhang, H., Che, Y., Wang, W., Lv, H., et al. Serenoa Repens induces growth arrest, apoptosis and inactivation of STAT3 signaling in human glioma cells. Technol Cancer Res Treat 14 (2015), 729–736.
130. Dong, X.Z., Huang, C.L., Yu, B.Y., Hu, Y., Mu, L.H., Liu, P., Effect of tenuifoliside A isolated from Polygala tenuifolia on the ERK and PI3K pathways in C6 glioma cells. Phytomedicine 21 (2014), 1178–1188.
131. Fulda, S., Betulinic acid for cancer treatment and prevention. Int J Mol Sci 9 (2008), 1096–1107.
132. Ehrhardt, H., Fulda, S., Führer, M., Debatin, K.M., Jeremias, I., Betulinic acid-induced apoptosis in leukemia cells. Leukemia 18 (2004), 1406–1412.
133. Shankar, E., Zhang, A., Franco, D., Gupta, S., Betulinic acid-mediated apoptosis in human prostate cancer cells involves p53 and nuclear factor-kappa B (NF-κB) pathways. Molecules, 22, 2017.
134. Su, D., Gao, Y.Q., Dai, W.B., Hu, Y., Wu, Y.F., Mei, Q.X., Helicteric acid, oleanic acid, and betulinic acid, three triterpenes from Helicteres angustifolia L., inhibit proliferation and induce apoptosis in HT-29 colorectal cancer cells via suppressing NF-κB and STAT3 Signaling. Evid Based Complement Altern Med, 2017, 2017, 5180707.
135. Gupta, M., Kaur, G., Aqueous extract from the Withania somnifera leaves as a potential anti-neuroinflammatory agent: a mechanistic study. J Neuroinflamm, 13, 2016, 193.
136. Sun, G.Y., Li, R., Cui, J., Hannink, M., Gu, Z., Fritsche, K.L., et al. Withania somnifera and its withanolides attenuate oxidative and inflammatory responses and up-regulate antioxidant responses in BV-2 microglial cells. Neuromolecular Med 18 (2016), 241–252.
137. Kataria, H., Kumar, S., Chaudhary, H., Kaur, G., Withania somnifera suppresses tumor growth of intracranial allograft of glioma cells. Mol Neurobiol 53 (2016), 4143–4158.
138. Abdallah, H.M., Al-Abd, A.M., El-Dine, R.S., El-Halawany, A.M., P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: a review. J Adv Res 6 (2015), 45–62.
139. He, L., Zhao, C., Yan, M., Zhang, L.Y., Xia, Y.Z., Inhibition of P-glycoprotein function by procyanidine on blood–brain barrier. Phytother Res 23 (2009), 933–937.
140. Zhao, B.X., Sun, Y.B., Wang, S.Q., Duan, L., Huo, Q.L., Ren, F., et al. Grape seed procyanidin reversal of p-glycoprotein associated multi-drug resistance via down-regulation of NF-κB and MAPK/ERK mediated YB-1 activity in A2780/T cells. PLoS One, 8, 2013, e71071.
141. Mahringer, A., Karamustafa, S., Klotz, D., Kahl, S., Konkimalla, V.B., Wang, Y., et al. Inhibition of P-glycoprotein at the blood–brain barrier by phytochemicals derived from traditional Chinese medicine. Cancer Genom Proteom 7 (2010), 191–205.
142. Nitsch, C., Hubauer, H., Distant blood–brain barrier opening in subfields of the rat hippocampus after intrastriatal injections of kainic acid but not ibotenic acid. Neurosci Lett 64 (1986), 53–58.
143. Lin, X., Zha, Y., Zeng, X.Z., Dong, R., Wang, Q.H., Wang, D.T., Role of the Wnt/β-catenin signaling pathway in inducing apoptosis and renal fibrosis in 5/6-nephrectomized rats. Mol Med Rep 15 (2017), 3575–3582.
144. Kim, K.I., Jeong, D.S., Yoon, T.J., Jung, E.C., Lee, J.H., Kim, C.D., Inhibition of collagen production by ICG-001, a small molecule inhibitor for Wnt/β-catenin signaling, in skin fibroblasts. J Dermatol Sci 86 (2017), 76–78.
145. Sato, M., Upregulation of the Wnt/β-catenin pathway induced by transforming growth factor-β in hypertrophic scars and keloids. Acta Derm Venereol 86 (2006), 300–307.
146. Fu, Y., Li, L., Hao, S., Guan, R., Fan, G., Shi, C., et al. Draft genome sequence of the Tibetan medicinal herb, Rhodiola crenulata. Gigascience 6 (2017), 1–5.
147. Mora, M.C., Bassa, L.M., Wong, K.E., Tirabassi, M.V., Arenas, R.B., Schneider, S.S., Rhodiola crenulata inhibits Wnt/β-catenin signaling in glioblastoma. J Surg Res 197 (2015), 247–255.
148. Bassa, L.M., Jacobs, C., Gregory, K., Henchey, E., Ser-Dolansky, J., Schneider, S.S., Rhodiola crenulata induces an early estrogenic response and reduces proliferation and tumorsphere formation over time in MCF7 breast cancer cells. Phytomedicine 23 (2016), 87–94.
149. Li, C., Zeng, M., Chi, H., Shen, J., Ng, T.B., Jin, G., et al. Trichosanthin increases granzyme B penetration into tumor cells by upregulation of CI-MPR on the cell surface. Oncotarget 8 (2017), 26460–26470.
150. Miao, J., Jiang, Y., Wang, D., Zhou, J., Fan, C., Jiao, F., et al. Trichosanthin suppresses the proliferation of glioma cells by inhibiting LGR5 expression and the Wnt/β-catenin signaling pathway. Oncol Rep 34 (2015), 2845–2852.
151. Nathan, C., Nitric oxide as a secretory product of mammalian cells. FASEB J 6 (1992), 3051–3064.
152. Valenti, S., Cuttica, C.M., Giusti, M., Giordano, G., Nitric oxide modulates Leydig cell function in vitro: is this a way of communication between the immune and endocrine system in the testis?. Ann N Y Acad Sci 876 (1999), 298–300.
153. Kim, C.S., Subedi, L., Park, K.J., Kim, S.Y., Choi, S.U., Kim, K.H., et al. Salicin derivatives from Salix glandulosa and their biological activities. Fitoterapia 106 (2015), 147–152.
154. 2 extract of mango ginger (Curcuma amada Roxb.) in human glioblastoma cells. J Complement Integr Med 12 (2015), 307–315.
155. Kong, C.S., Kim, K.H., Choi, J.S., Kim, J.E., Park, C., Jeong, J.W., Salicin, an extract from white willow bark, inhibits angiogenesis by blocking the ROS-ERK pathways. Phytother Res 28 (2014), 1246–1251.
156. Kim, C.S., Subedi, L., Kwon, O.W., Park, H.B., Kim, S.Y., Choi, S.U., et al. Wasabisides A-E, lignan glycosides from the roots of Wasabia Japonica. J Nat Prod 79 (2016), 2652–2657.
157. Kim, C.S., Subedi, L., Kim, S.Y., Choi, S.U., Kim, K.H., Lee, K.R., Diterpenes from the trunk of Abies holophylla and their potential neuroprotective and anti-inflammatory activities. J Nat Prod 79 (2016), 387–394.
158. Reuter, S., Gupta, S.C., Chaturvedi, M.M., Aggarwal, B.B., Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic Biol Med 49 (2010), 1603–1616.
159. Weitzman, S.A., Gordon, L.I., Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 76 (1990), 655–663.
160. Rosin, M.P., Saad, D.Z., Ward, A.J., Anwar, W.A., Involvement of inflammatory reactions and elevated cell proliferation in the development of bladder cancer in schistosomiasis patients. Mutat Res 305 (1994), 283–292.
161. Frenkel, K., Carcinogen-mediated oxidant formation and oxidative DNA damage. Pharmacol Ther 53 (1992), 127–166.
162. Tian, X., Peng, J., Zhong, J., Yang, M., Pang, J., Lou, J., et al. β-Caryophyllene protects in vitro neurovascular unit against oxygen-glucose deprivation and re-oxygenation-induced injury. J Neurochem 139 (2016), 757–768.
163. Park, K.R., Nam, D., Yun, H.M., Lee, S.G., Jang, H.J., Sethi, G., et al. β-Caryophyllene oxide inhibits growth and induces apoptosis through the suppression of PI3K/AKT/mTOR/S6K1 pathways and ROS-mediated MAPKs activation. Cancer Lett 312 (2011), 178–188.
164. Wang, Y.F., Gu, Y.T., Qin, G.H., Zhong, L., Meng, Y.N., Curcumin ameliorates the permeability of the blood–brain barrier during hypoxia by upregulating heme oxygenase-1 expression in brain microvascular endothelial cells. J Mol Neurosci 51 (2013), 344–351.
165. Xiao, L., Ding, M., Fernandez, A., Zhao, P., Jin, L., Li, X., Curcumin alleviates lumbar radiculopathy by reducing neuroinflammation, oxidative stress and nociceptive factors. Eur Cell Mater 33 (2017), 279–293.
166. Santos-Parker, J.R., Strahler, T.R., Bassett, C.J., Bispham, N.Z., Chonchol, M.B., Seals, D.R., Curcumin supplementation improves vascular endothelial function in healthy middle-aged and older adults by increasing nitric oxide bioavailability and reducing oxidative stress. Aging 9 (2017), 187–208.
167. Park, J.H., Choi, J.W., Ju, E.J., Pae, A.N., Park, K.D., Antioxidant and anti-inflammatory activities of a natural compound, shizukahenriol, through Nrf2 activation. Molecules 20 (2015), 15989–16003.
168. Dietrich, J.B., Alteration of blood–brain barrier function by methamphetamine and cocaine. Cell Tissue Res 336 (2009), 385–392.